[Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
The development of vasodilator drugs that open the K+ channels in blood vessels has been of great academic and practical interest. The K-channel openers (cromakalim, pinacidil and nicorandil) decreased afterload or preload due to their vasodilator action. In addition, K-channel openers produced a cardioprotective effect in lower doses that did not affect coronary blood flow or blood pressure. It is highly expected to be useful for treatment of congestive heart failure.
Satoh
K
K
Department of Pharmacology, Faculty of Medicine, Tottori University.
D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D019806:Cromakalim; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D015640:Ion Channel Gating / Q000187:drug effects*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D020108:Nicorandil; D020110:Pinacidil; D015221:Potassium Channels / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D001578:Benzopyrans; D002121:Calcium Channel Blockers; D006146:Guanidines; D015221:Potassium Channels; D011758:Pyrroles; D014665:Vasodilator Agents; D019806:Cromakalim; D009536:Niacinamide; D020108:Nicorandil; D020110:Pinacidil